Oxaliplatin News and Research

RSS

Data results of NCI-MATCH trial in tumors with DNA mismatch repair deficiencies

Final results are published from an evaluation of 42 patients treated with the immune checkpoint inhibitor nivolumab in the large multi-arm precision medicine trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131).

20 Dec 2019

Innovative compound kills cancer cells, minimizes damage to normal tissues

Most of the current clinical anti-tumor drugs used in chemotherapy move around in the patient's blood after intake and are unable to pinpoint the targeted tumor. As a result, while killing the tumor cells, the healthy cells may also be killed as "collateral damage", leading to undesired side effects.

3 Oct 2019

Roswell Park receives more than $15 million in grants for cancer research

Roswell Park Comprehensive Cancer Center researchers have received more than a dozen recent grant awards totaling more than $15.4 million.

14 Aug 2019

Processed aconite root could relieve neuropathic pain in murine peripheral neuropathy

The root of Aconitum carmichaeli, is a crude drug used in traditional Chinese or Japanese kampo medicine to treat pain associated with coldness.

11 Apr 2019

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

$Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer$

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

SLU researchers turn off excruciating chemo pain in animal model

In a recent paper published in the journal Pain, Saint Louis University researchers describe their success in an animal model in turning off the excruciating pain that often accompanies a colorectal cancer drug.

26 Mar 2018

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

A randomized trial in 650 patients has confirmed the safety and efficacy of a new second line treatment for metastatic colorectal cancer, researchers report at the ESMO Asia 2017 Congress.

20 Nov 2017

FDA grants approval for new biosimilar to treat multiple types of cancer

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

14 Sep 2017

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

The superiority of docetaxel based triplet therapy over standard care in patients with resectable oesophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.

8 Sep 2017

Study shows effectiveness of 3 months of chemotherapy in colon cancer patients after surgery

After surgery for lymph-node positive colon cancer (stage III), some patients may only need half of the long-standing standard course of chemotherapy.

5 Jun 2017

Study suggests revolutionary way to make cancer cells more susceptible to existing chemotherapies

The same signal that drives aggressive growth in a deadly cancer cell type also triggers coping mechanisms that make it "notoriously" hard to kill, according to a study published online December 15 in Cell. When stressed, this cell type - far more than most cancer cells - encases its genetic messages in protein globs called "stress granules" that lessen the effect of chemotherapies.

16 Dec 2016

IQWiG finds colorectal cancer drug combination has added benefit only for some patients

The fixed combination of trifluridine/tipiracil has been approved since April 2016 for the treatment of metastatic colorectal cancer.

23 Nov 2016

Novel therapy offers hope for effective treatment of intractable metastatic cancers

Cancer treatments that mobilize the body's immune system to fight the disease have generated a lot of excitement in the past few years.

19 Sep 2016

Oxaliplatin News and Research

Data results of NCI-MATCH trial in tumors with DNA mismatch repair deficiencies

Innovative compound kills cancer cells, minimizes damage to normal tissues

Roswell Park receives more than $15 million in grants for cancer research

Processed aconite root could relieve neuropathic pain in murine peripheral neuropathy

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

SLU researchers turn off excruciating chemo pain in animal model

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

FDA grants approval for new biosimilar to treat multiple types of cancer

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

Study shows effectiveness of 3 months of chemotherapy in colon cancer patients after surgery

Study suggests revolutionary way to make cancer cells more susceptible to existing chemotherapies

IQWiG finds colorectal cancer drug combination has added benefit only for some patients

Novel therapy offers hope for effective treatment of intractable metastatic cancers

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News